Concepedia

Author

John Bell

AstraZeneca (United Kingdom)ORCID

Also Known As

J Bell, J P Bell, J. Bell, J. P. Bell, J.P. Bell, John Bell, John P Bell, John P. Bell, John Perkins Bell

37

Publications

394

Citations

13

H-Index

40

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (Sweden)Loughborough UniversityUppsala UniversitySumitomo Dainippon Pharma (Japan)
JB

About

John Bell is an author at AstraZeneca (United Kingdom) specializing in medicine, immunotherapy, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

110

2

Natural Sciences

2

2

37

3

Allergy

2

2

29

4

Biochemistry

2

2

37

5

Allergy Medicine

1

1

18

John Bell

×

12

Publications

290

Citations

11

H-Index

YearCitations

Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment (CARBON) study

Alex Wilkinson, Ekaterina Maslova, Christer Janson,

Thorax

2024

39

Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study

Ashraf Alzaabi, John Bell, Felicia Montero-Arias,

Advances in Therapy

2023

35

Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs

John Bell, Salah I. Mosfer, Derek Lang,

American Journal of Physiology-Heart and Circulatory Physiology

2001

34

First‐in‐Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well‐Tolerated

Sam Jackson, Albert F. Candia, Stephen Delaney,

Clinical Pharmacology & Therapeutics

2017

29

Intratracheal and oral administration of SM‐276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer

Erina Koga‐Yamakawa, Simon J. Dovedi, Masashi Murata,

International Journal of Cancer

2012

27

Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme

Alex Wilkinson, Ekaterina Maslova, Christer Janson,

Advances in Therapy

2022

22

Immunosuppressive and antitumor activity of periodate oxidation product of beta-D-ribosyl-6-methylthiopurine.

John Bell, M. L. Faures, G. A. LePage,

PubMed

1968

21

Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848

Stephen Delaney, Mark Biffen, Justine Maltby,

BMJ Open Respiratory Research

2016

21

Mechanism of Action of Inhibition of Allergic Immune Responses by a Novel Antedrug TLR7 Agonist

Hiroyuki Matsui, Hideyuki Tomizawa, Kazuo Eiho,

The Journal of Immunology

2012

18

Studies on immunosuppression by purine nucleoside analogues—I

Roland H. Gisler, John Bell

Biochemical Pharmacology

1969

17

Page 1